DK2325207T3 - Fc-varianter med ændret binding til FcRn - Google Patents
Fc-varianter med ændret binding til FcRn Download PDFInfo
- Publication number
- DK2325207T3 DK2325207T3 DK10178237.3T DK10178237T DK2325207T3 DK 2325207 T3 DK2325207 T3 DK 2325207T3 DK 10178237 T DK10178237 T DK 10178237T DK 2325207 T3 DK2325207 T3 DK 2325207T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- binding
- polypeptide
- variant
- igg
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (8)
1. Polypeptid omfattende en Fc-variant af et humant IgG-Fc-polypeptid, hvor Fc-varianten har fra én til fem aminosyremodifikationer sammenlignet med et humant lgG1-, lgG2-, lgG3- eller lgG4-moder-Fc-polypeptid som defineret i figur 2, hvor Fc-varianten omfatter en tryptophan i position 308, hvor Fc-varianten udviser øget binding til FcRn sammenlignet med det humane lgG1-, lgG2-, lgG3- eller lgG4-moder-Fc-polypeptid, og hvor nummereringen er i overensstemmelse med EU-indekset i Kabat et al.
2. Polypeptid ifølge krav 1, hvor polypeptidet er et antistof.
3. Polypeptid ifølge et hvilket som helst af kravene 1 til 2, hvor polypeptidet er en Fc-fusion.
4. Polypeptid ifølge et hvilket som helst af kravene 2 til 3, hvor polypeptidet har specificitet for et målmolekyle, der er udvalgt fra gruppen bestående af et cytokin, en opløselig proteinfaktor og et protein, der er udtrykt på cancerceller.
5. Fremgangsmåde til fremstilling af et polypeptid ifølge krav 1 til 4, hvilken fremgangsmåde omfatter at tilvejebringe en celle omfattende en nukleinsyre, som koder for polypeptidet, hvor cellen dyrkes under betingelser, som er egnede til ekspression af polypeptidet.
6. Fremgangsmåde ifølge krav 5, hvor nukleinsyren er indeholdt i en ekspressionsvektor.
7. Værtscelle omfattende en nukleinsyre, som koder for et polypeptid ifølge krav 1 til 4.
8. Ekspressionsvektor, hvor ekspressionsvektoren koder for et polypeptid ifølge krav 1 til 4.
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62776304P | 2004-11-12 | 2004-11-12 | |
| US64288605P | 2005-01-11 | 2005-01-11 | |
| US64950805P | 2005-02-02 | 2005-02-02 | |
| US66246805P | 2005-03-15 | 2005-03-15 | |
| US66931105P | 2005-04-06 | 2005-04-06 | |
| US68160705P | 2005-05-16 | 2005-05-16 | |
| US69020005P | 2005-06-13 | 2005-06-13 | |
| US69660905P | 2005-07-05 | 2005-07-05 | |
| US70301805P | 2005-07-27 | 2005-07-27 | |
| US72645305P | 2005-10-12 | 2005-10-12 | |
| EP05851619A EP1817340B1 (en) | 2004-11-12 | 2005-11-14 | Fc variants with altered binding to fcrn |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2325207T3 true DK2325207T3 (da) | 2017-06-06 |
Family
ID=36337300
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10178237.3T DK2325207T3 (da) | 2004-11-12 | 2005-11-14 | Fc-varianter med ændret binding til FcRn |
| DK05851619.6T DK1817340T3 (da) | 2004-11-12 | 2005-11-14 | Fc-varianter med ændret binding til fcrn |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05851619.6T DK1817340T3 (da) | 2004-11-12 | 2005-11-14 | Fc-varianter med ændret binding til fcrn |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US9200079B2 (da) |
| EP (6) | EP2332985A3 (da) |
| JP (1) | JP4652414B2 (da) |
| KR (2) | KR101019525B1 (da) |
| CN (1) | CN102746404B (da) |
| AU (2) | AU2005304624B2 (da) |
| BR (1) | BRPI0517837A (da) |
| CA (1) | CA2587617C (da) |
| DK (2) | DK2325207T3 (da) |
| IL (2) | IL183158A (da) |
| WO (1) | WO2006053301A2 (da) |
Families Citing this family (245)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7183387B1 (en) * | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7408041B2 (en) | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| JP4280803B2 (ja) | 2000-12-08 | 2009-06-17 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 慢性リンパ性白血病細胞株および抗体を産生するためのその使用 |
| US20060057651A1 (en) | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US9249229B2 (en) | 2000-12-08 | 2016-02-02 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
| WO2005063815A2 (en) * | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| PL2213683T3 (pl) | 2004-08-04 | 2013-10-31 | Mentrik Biotech Llc | WARIANTY REGIONÓW Fc |
| US9492400B2 (en) | 2004-11-04 | 2016-11-15 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
| DK2325207T3 (da) | 2004-11-12 | 2017-06-06 | Xencor Inc | Fc-varianter med ændret binding til FcRn |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP1871808A2 (en) * | 2005-03-31 | 2008-01-02 | Xencor, Inc. | Fc VARIANTS WITH OPTIMIZED PROPERTIES |
| US8309690B2 (en) | 2005-07-01 | 2012-11-13 | Medimmune, Llc | Integrated approach for generating multidomain protein therapeutics |
| US7790655B2 (en) | 2005-10-14 | 2010-09-07 | Medimmune, Llc | Cell display of antibody libraries |
| WO2007070682A2 (en) | 2005-12-15 | 2007-06-21 | Massachusetts Institute Of Technology | System for screening particles |
| PL2463305T3 (pl) | 2006-01-12 | 2017-02-28 | Alexion Pharmaceuticals, Inc. | Przeciwciała przeciw OX-2/CD200 i ich zastosowania |
| WO2007114319A1 (ja) | 2006-03-31 | 2007-10-11 | Chugai Seiyaku Kabushiki Kaisha | 抗体の血中動態を制御する方法 |
| ES2776100T3 (es) | 2006-03-31 | 2020-07-29 | Massachusetts Inst Technology | Sistema para el suministro dirigido de agentes terapéuticos |
| CN101573141B (zh) | 2006-05-15 | 2016-05-04 | 麻省理工学院 | 用于功能性颗粒的聚合物 |
| US9381477B2 (en) | 2006-06-23 | 2016-07-05 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
| US20100143254A1 (en) * | 2006-10-16 | 2010-06-10 | Medimmune, Llc | Molecules with reduced half-lives, compositions and uses thereof |
| WO2008147456A2 (en) * | 2006-11-20 | 2008-12-04 | Massachusetts Institute Of Technology | Drug delivery systems using fc fragments |
| US8067179B2 (en) | 2006-11-30 | 2011-11-29 | Research Development Foundation | Immunoglobulin libraries |
| UY30838A1 (es) * | 2006-12-26 | 2008-07-31 | Centro Inmunologia Molecular | Composicion farmacéutica que comprende un anticuerpo monoclonal anti cd6 utilizado en el diagnostico y tratamiento de la artritis reumatoide |
| WO2008098165A2 (en) | 2007-02-09 | 2008-08-14 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
| EP1975178A1 (en) * | 2007-03-30 | 2008-10-01 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Transcytotic modular antibody |
| WO2008124634A1 (en) * | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Polymer-encapsulated reverse micelles |
| WO2008124632A1 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Amphiphilic compound assisted nanoparticles for targeted delivery |
| AU2008247819B2 (en) * | 2007-05-01 | 2013-02-14 | Research Development Foundation | Immunoglobulin Fc libraries |
| EP2176298B1 (en) | 2007-05-30 | 2017-11-15 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| WO2009014744A1 (en) | 2007-07-25 | 2009-01-29 | Alexion Pharmaceutical, Inc. | Methods and compositions for treating autoimmune disease |
| PE20140196A1 (es) | 2007-08-09 | 2014-03-19 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| US9096651B2 (en) | 2007-09-26 | 2015-08-04 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
| CA2978687C (en) | 2007-09-26 | 2020-02-18 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
| WO2009051837A2 (en) | 2007-10-12 | 2009-04-23 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| ES2532461T3 (es) * | 2007-12-26 | 2015-03-27 | Xencor, Inc. | Variantes de FC con enlazamiento alterado a FCRN |
| KR20100115360A (ko) * | 2008-02-05 | 2010-10-27 | 브리스톨-마이어스 스큅 컴퍼니 | 알파 ５-베타 １ 항체 및 이의 용도 |
| US20110059078A1 (en) | 2008-02-08 | 2011-03-10 | Medimmune, Llc | Anti-ifnar1 antibodies with reduced fc ligand affinity |
| MX2010010085A (es) | 2008-03-14 | 2011-03-29 | Biocon Ltd | Un anticuerpo monoclonal y el metodo para su uso. |
| EP3045475B1 (en) | 2008-04-02 | 2017-10-04 | MacroGenics, Inc. | Bcr-complex-specific antibodies and methods of using same |
| JP4954326B2 (ja) | 2008-04-11 | 2012-06-13 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
| CA2726845C (en) * | 2008-06-04 | 2017-09-26 | Macrogenics, Inc. | Antibodies with altered binding to fcrn and methods of using same |
| JP2011526595A (ja) * | 2008-06-30 | 2011-10-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 免疫グロブリンのフォールディングパターンを有するタンパク質を最適化するための方法 |
| US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
| US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
| US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
| US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
| AU2013203391B2 (en) * | 2008-10-14 | 2016-03-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| TWI572359B (zh) * | 2008-10-14 | 2017-03-01 | 建南德克公司 | 免疫球蛋白變異體及其用途 |
| WO2010096394A2 (en) | 2009-02-17 | 2010-08-26 | Redwood Biosciences, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
| AU2016213792B2 (en) * | 2009-03-20 | 2017-06-22 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Optimized Fc variants |
| EP2233500A1 (en) * | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
| CN102549016B (zh) * | 2009-06-30 | 2015-05-06 | 研究发展基金会 | 免疫球蛋白fc多肽 |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| PT2486141T (pt) | 2009-10-07 | 2018-05-09 | Macrogenics Inc | Polipéptidos contendo uma região fc que apresenta uma função efectora melhorada, devido a modificações do grau de fucosilação, e métodos para a sua utilização |
| CN102933604B (zh) | 2010-02-23 | 2016-04-06 | 赛诺菲 | 抗-α2整联蛋白抗体及其用途 |
| ME03447B (me) | 2010-03-04 | 2020-01-20 | Macrogenics Inc | Anтitela reakтivna sa b7-нз, njihovi imunološki akтivni fragmenтi i upotreba |
| US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
| TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| NZ603226A (en) | 2010-04-30 | 2015-02-27 | Alexion Pharma Inc | Anti-c5a antibodies and methods for using the antibodies |
| US9815890B2 (en) | 2010-06-22 | 2017-11-14 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the C3d fragment of complement component 3 |
| EP2603526A1 (en) | 2010-08-13 | 2013-06-19 | Medimmune Limited | Monomeric polypeptides comprising variant fc regions and methods of use |
| WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| WO2012032080A1 (en) | 2010-09-07 | 2012-03-15 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H | Stabilised human fc |
| UA112062C2 (uk) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| BR112013009083B1 (pt) | 2010-10-13 | 2021-08-10 | Janssen Biotech, Inc. | Anticorpos humanos para oncostatina m, seu processo de fabricação, fragmento de ligação a antígeno, composição farmacêutica, polinucleotídeo isolado, célula hospedeira recombinante estavelmente transformada ou transfectada |
| SG190727A1 (en) | 2010-11-30 | 2013-07-31 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| AU2012205301B2 (en) | 2011-01-14 | 2017-01-05 | Redwood Bioscience, Inc. | Aldehyde-tagged immunoglobulin polypeptides and method of use thereof |
| TW201244737A (en) | 2011-02-03 | 2012-11-16 | Alexion Pharma Inc | Use of an anti-CD200 antibody for prolonging the survival of allografts |
| US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
| JP6228014B2 (ja) | 2011-02-07 | 2017-11-08 | リサーチ ディベロップメント ファウンデーション | 操作された免疫グロブリンＦｃポリペプチド |
| JP6032818B2 (ja) | 2011-02-25 | 2016-11-30 | 中外製薬株式会社 | ＦｃγＲＩＩｂ特異的Ｆｃ抗体 |
| LT2691417T (lt) | 2011-03-29 | 2018-10-25 | Roche Glycart Ag | Antikūno fc variantai |
| RU2013148071A (ru) * | 2011-04-01 | 2015-05-10 | Президент Энд Феллоуз Ов Харвард Колледж | Аналогичное диализу терапевтическое (dlt) устройство |
| MX356517B (es) | 2011-06-28 | 2018-06-01 | Inhibrx Llc | Polipéptidos de fusión de serpina y métodos de uso de los mismos. |
| US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
| TWI687441B (zh) | 2011-06-30 | 2020-03-11 | 中外製藥股份有限公司 | 異源二聚化多胜肽 |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| US20150050269A1 (en) | 2011-09-30 | 2015-02-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
| EP2762166B1 (en) | 2011-09-30 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecules for promoting elimination of antigens |
| TW201817745A (zh) * | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| RU2722829C9 (ru) * | 2011-09-30 | 2020-09-22 | Чугаи Сейяку Кабусики Кайся | Антигенсвязывающая молекула, индуцирующая иммунный ответ на антиген-мишень |
| AU2012336069A1 (en) | 2011-11-07 | 2014-05-22 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
| BR112014013081A2 (pt) | 2011-11-30 | 2020-10-20 | Chugai Seiyaku Kabushiki Kaisha | veículo contendo fármaco em célula para formação de um complexo imune |
| SG11201403444UA (en) * | 2011-12-21 | 2014-07-30 | Amgen Inc | Variant fc-polypeptides with enhanced binding to the neonatal fc receptor |
| KR102041412B1 (ko) * | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | 면역글로불린 Ｆｃ 단편 유도체 |
| SG10201704849PA (en) | 2012-02-09 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Modified fc region of antibody |
| TWI617577B (zh) | 2012-02-24 | 2018-03-11 | 中外製藥股份有限公司 | 經ＦｃγＲＩＩＢ促進抗原消失之抗原結合分子 |
| CN104428317B (zh) * | 2012-04-27 | 2018-08-28 | 生物蛋白有限公司 | 修饰的抗体区及其用途 |
| JPWO2013180201A1 (ja) * | 2012-05-30 | 2016-01-21 | 中外製薬株式会社 | 会合化した抗原を消失させる抗原結合分子 |
| CA2874721A1 (en) * | 2012-05-30 | 2013-12-05 | Tomoyuki Igawa | Target tissue-specific antigen-binding molecule |
| US11142563B2 (en) | 2012-06-14 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing modified Fc region |
| EP2863954A1 (en) | 2012-06-21 | 2015-04-29 | Indiana University Research and Technology Corporation | Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function |
| US11180572B2 (en) | 2012-07-06 | 2021-11-23 | Genmab B.V. | Dimeric protein with triple mutations |
| PT2869845T (pt) * | 2012-07-06 | 2019-12-09 | Genmab Bv | Proteína dimérica com mutações triplas |
| HRP20211641T1 (hr) | 2012-07-13 | 2022-02-04 | Roche Glycart Ag | Bispecifična protutijela anti-vegf/anti-ang-2 i njihova primjena u liječenju vaskularnih očnih bolesti |
| WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
| SG11201500873XA (en) | 2012-08-24 | 2015-04-29 | Chugai Pharmaceutical Co Ltd | Fcgriib-specific fc region variant |
| WO2014104165A1 (ja) | 2012-12-27 | 2014-07-03 | 中外製薬株式会社 | ヘテロ二量化ポリペプチド |
| KR20240123420A (ko) | 2013-01-10 | 2024-08-13 | 젠맵 비. 브이 | 인간 IgG1 Fc 영역 변이체 및 그의 용도 |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| EP2970921B1 (en) | 2013-03-15 | 2018-09-19 | aTyr Pharma, Inc. | Histidyl-trna synthetase-fc conjugates |
| AU2014250434B2 (en) | 2013-04-02 | 2019-08-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
| PE20151807A1 (es) | 2013-04-29 | 2015-12-02 | Hoffmann La Roche | Anticuerpos modificados de union a fcrn humano y metodo de utilizacion |
| EP3936148A1 (en) | 2013-07-23 | 2022-01-12 | Biocon Limited | Use of a cd6 binding partner and method based thereon |
| EP3038657A2 (en) | 2013-08-28 | 2016-07-06 | Bioasis Technologies Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
| CN113667012B (zh) | 2013-10-02 | 2024-07-12 | 免疫医疗有限责任公司 | 中和抗甲型流感抗体及其用途 |
| WO2015054039A1 (en) * | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Fc CONTAINING POLYPEPTIDES HAVING INCREASED BINDING TO FcGammaRIIB |
| AU2014347565B2 (en) | 2013-11-11 | 2020-08-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing modified antibody variable region |
| CA2931296C (en) | 2013-12-04 | 2024-04-23 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules |
| RU2698969C2 (ru) | 2014-01-15 | 2019-09-02 | Ф.Хоффманн-Ля Рош Аг | Варианты fc-области с улучшенной способностью связываться с белком а |
| NZ711451A (en) | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| CN106232139A (zh) | 2014-04-11 | 2016-12-14 | 免疫医疗有限责任公司 | 双特异性her2抗体 |
| CN106413750B (zh) | 2014-05-16 | 2022-04-29 | 免疫医疗有限责任公司 | 具有增强的治疗和诊断特性的带有改变的新生儿Fc受体结合的分子 |
| CN104122392B (zh) * | 2014-06-24 | 2016-05-25 | 上海交通大学医学院附属瑞金医院 | 检测ccl15趋化因子的试剂在制备筛选甲状腺滤泡癌试剂中的应用 |
| EP3161002A1 (en) | 2014-06-27 | 2017-05-03 | Innate Pharma | MULTISPECIFIC NKp46 BINDING PROTEINS |
| JP6702893B2 (ja) * | 2014-06-27 | 2020-06-03 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | 多重特異的抗原結合タンパク質 |
| USD801353S1 (en) * | 2014-09-11 | 2017-10-31 | Express Scripts, Inc. | Display screen with a graphical user interface |
| USD791797S1 (en) * | 2014-09-11 | 2017-07-11 | Express Scripts, Inc. | Display screen with a graphical user interface |
| USD791796S1 (en) * | 2014-09-11 | 2017-07-11 | Express Scripts, Inc. | Display screen with a graphical user interface |
| WO2016069574A1 (en) * | 2014-10-27 | 2016-05-06 | Inhibrx Lp | Serpin fusion polypeptides and methods of use thereof |
| RU2713131C1 (ru) * | 2014-11-06 | 2020-02-03 | Ф. Хоффманн-Ля Рош Аг | ВАРИАНТЫ Fc-ОБЛАСТИ С МОДИФИЦИРОВАННЫМИ СВОЙСТВАМИ СВЯЗЫВАНИЯ FcRn И БЕЛКА А |
| TW202432590A (zh) | 2014-12-19 | 2024-08-16 | 日商中外製藥股份有限公司 | 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法 |
| US9767555B2 (en) * | 2015-01-05 | 2017-09-19 | Case Western Reserve University | Disease characterization from fused pathology and radiology data |
| CN107428818A (zh) | 2015-01-29 | 2017-12-01 | 密西根州立大学校董会 | 隐藏多肽及其用途 |
| CN114773469A (zh) * | 2015-02-05 | 2022-07-22 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用 |
| JP6724023B2 (ja) | 2015-02-09 | 2020-07-15 | リサーチ ディベロップメント ファウンデーション | 改善された補体活性化を示す操作された免疫グロブリンｆｃポリペプチド |
| EP3313881A1 (en) | 2015-06-23 | 2018-05-02 | Innate Pharma | Multispecific nk engager proteins |
| CN105254764A (zh) * | 2015-08-27 | 2016-01-20 | 上海康岱生物医药技术有限公司 | ACVR1-Fc融合蛋白及其制法和用途 |
| WO2017040380A2 (en) | 2015-08-28 | 2017-03-09 | Research Development Foundation | Engineered antibody fc variants |
| HUE056243T2 (hu) | 2015-12-15 | 2022-02-28 | Gilead Sciences Inc | Emberi immunhiányt okozó vírust semlegesítõ ellenanyagok |
| CA3008678A1 (en) | 2015-12-21 | 2017-06-29 | Bristol-Myers Squibb Company | Variant antibodies for site-specific conjugation |
| US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| EP3432927A4 (en) | 2016-03-24 | 2019-11-20 | Gensun Biopharma Inc. | TRIPLE-SPECIFIC INHIBITORS FOR CANCER TREATMENT |
| US10961311B2 (en) | 2016-04-15 | 2021-03-30 | Macrogenics, Inc. | B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof |
| WO2017189432A1 (en) | 2016-04-26 | 2017-11-02 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
| ES2963807T3 (es) | 2016-06-08 | 2024-04-02 | Xencor Inc | Tratamiento de enfermedades relacionadas con la IgG4 con anticuerpos anti-CD19 de reticulación a CD32B |
| JP2019525772A (ja) | 2016-07-08 | 2019-09-12 | スターテン・バイオテクノロジー・ベー・フェー | 抗ａｐｏｃ３抗体およびその使用方法 |
| MX2019001458A (es) | 2016-08-02 | 2019-07-04 | Visterra Inc | Polipeptidos modificados y usos de los mismos. |
| KR20230079499A (ko) | 2016-08-05 | 2023-06-07 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
| MA45919A (fr) | 2016-08-12 | 2019-06-19 | Janssen Biotech Inc | Conception d'anticorps modifiés et d'autres molécules contenant un domaine fc présentant des fonctions d'agonisme et d'effecteur améliorées |
| CN107759697B (zh) | 2016-08-19 | 2023-03-24 | 安源医药科技（上海）有限公司 | 制备融合蛋白的方法 |
| CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技（上海）有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
| WO2018032638A1 (zh) | 2016-08-19 | 2018-02-22 | 安源医药科技（上海）有限公司 | 用于构建融合蛋白的连接肽 |
| SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
| US11286295B2 (en) * | 2016-10-20 | 2022-03-29 | Sanofi | Anti-CHIKV monoclonal antibodies directed against the E2 structural protein |
| DK3529274T3 (da) | 2016-10-21 | 2024-06-17 | Biocon Ltd | Monoklonalt antistof og fremgangsmåde til anvendelse til behandling af lupus |
| CN109071656B (zh) | 2017-01-05 | 2021-05-18 | 璟尚生物制药公司 | 检查点调节物拮抗剂 |
| KR20190129868A (ko) | 2017-02-17 | 2019-11-20 | 데날리 테라퓨틱스 인크. | 조작된 트란스페린 수용체 결합 폴리펩티드 |
| KR101913743B1 (ko) | 2017-04-07 | 2018-11-01 | 국민대학교 산학협력단 | 혈중 반감기 연장을 위한 항체 Fc 변이체들 |
| AU2018256435A1 (en) | 2017-04-20 | 2019-11-07 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
| EP3612560A1 (en) | 2017-04-21 | 2020-02-26 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| MX2019014576A (es) | 2017-06-05 | 2020-07-29 | Janssen Biotech Inc | Anticuerpos multiespecíficos manipulados genéticamente y otras proteínas multiméricas con mutaciones asimétricas en la región ch2-ch3. |
| TWI728250B (zh) | 2017-06-21 | 2021-05-21 | 美商基利科學股份有限公司 | 靶向hiv gp120及cd3之多特異性抗體 |
| MX2020001052A (es) | 2017-07-27 | 2022-05-18 | Alexion Pharma Inc | Formulaciones de anticuerpos anti-c5 de alta concentracion. |
| EP3665195A4 (en) * | 2017-08-11 | 2021-05-19 | Research Development Foundation | MANIPULATED ANTIBODY FC VARIANTS FOR INCREASED SERUM HALF-VALUE |
| WO2019067499A1 (en) | 2017-09-27 | 2019-04-04 | Alexion Pharmaceuticals, Inc. | BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY |
| WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| CA3080187A1 (en) | 2017-10-26 | 2019-05-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) |
| WO2019087115A1 (en) | 2017-10-31 | 2019-05-09 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| US10538583B2 (en) | 2017-10-31 | 2020-01-21 | Staten Biotechnology B.V. | Anti-APOC3 antibodies and compositions thereof |
| CN111741973A (zh) | 2017-12-19 | 2020-10-02 | 洛克菲勒大学 | 具有改进的效应子功能的人IgG Fc结构域变体 |
| WO2019126536A1 (en) | 2017-12-20 | 2019-06-27 | Alexion Pharmaceuticals Inc. | Humanized anti-cd200 antibodies and uses thereof |
| TW201940512A (zh) * | 2018-01-26 | 2019-10-16 | 美商健臻公司 | 具有與ＦｃＲｎ增進的結合及延長的半衰期之Ｆｃ變異體 |
| US20200040103A1 (en) | 2018-03-14 | 2020-02-06 | Genentech, Inc. | Anti-klk5 antibodies and methods of use |
| EP3765494A4 (en) | 2018-03-15 | 2022-03-23 | Chugai Seiyaku Kabushiki Kaisha | ANTI-DENGUE VIRUS ANTIBODIES WITH CROSS-REACTIVITY AGAINST ZIKA VIRUS AND METHODS OF USE |
| US20210154188A1 (en) | 2018-04-02 | 2021-05-27 | Silverback Therapeutics, Inc. | Alk5 inhibitors, conjugates, and uses thereof |
| EP4410379A3 (en) | 2018-05-16 | 2024-10-02 | CSL Ltd. | Soluble complement receptor type 1 variants and uses thereof |
| JP2021525799A (ja) | 2018-05-25 | 2021-09-27 | シルバーバック セラピューティックス インコーポレイテッド | アミノ−ピラジンカルボキサミド化合物、コンジュゲート、およびそれらの使用 |
| EP3802611A2 (en) | 2018-06-01 | 2021-04-14 | Novartis AG | Binding molecules against bcma and uses thereof |
| EP3813880A4 (en) | 2018-06-29 | 2022-07-13 | Gensun Biopharma Inc. | ANTITUMORS IMMUNOTEST POINT REGULATOR ANTAGONISTS |
| CN112368052A (zh) | 2018-07-03 | 2021-02-12 | 吉利德科学公司 | 靶向hiv gp120的抗体和使用方法 |
| CN108872598B (zh) * | 2018-07-09 | 2021-05-11 | 中国人民解放军军事科学院军事医学研究院 | 一种B型金葡菌肠毒素的AlphaLISA检测试剂盒 |
| AR114550A1 (es) | 2018-08-10 | 2020-09-16 | Chugai Pharmaceutical Co Ltd | Moléculas de unión al antígeno anti-cd137 y sus usos |
| US20220048895A1 (en) | 2018-09-12 | 2022-02-17 | Silverback Therapeutics, Inc. | Substituted benzazepine compounds, conjugates, and uses thereof |
| AU2019339344A1 (en) | 2018-09-12 | 2021-03-18 | Silverback Therapeutics, Inc. | Compositions for the treatment of disease with immune stimulatory conjugates |
| CN110950964B (zh) | 2018-09-26 | 2021-06-18 | 安源医药科技（上海）有限公司 | 突变型单链人凝血因子viii融合蛋白及其制备方法与用途 |
| WO2020088164A1 (zh) | 2018-11-01 | 2020-05-07 | 山东新时代药业有限公司 | 双特异性抗体及其用途 |
| US20220048981A1 (en) | 2018-12-05 | 2022-02-17 | Bica Therapeutics Inc. | Modified product of fc domain of antibody |
| US20220098310A1 (en) | 2018-12-06 | 2022-03-31 | Alexion Pharmaceuticals, Inc. | Anti-alk2 antibodies and uses thereof |
| WO2020181040A1 (en) | 2019-03-06 | 2020-09-10 | Silverback Therapeutics, Inc. | Cyclic amino-pyrazinecarboxamide compounds and uses thereof |
| KR20210149779A (ko) | 2019-04-10 | 2021-12-09 | 추가이 세이야쿠 가부시키가이샤 | Fc 영역 개변 항체의 정제 방법 |
| EP3986474A1 (en) | 2019-06-19 | 2022-04-27 | Silverback Therapeutics, Inc. | Anti-mesothelin antibodies and immunoconjugates thereof |
| US10851157B2 (en) | 2019-07-01 | 2020-12-01 | Gensun Biopharma, Inc. | Antagonists targeting the TGF-β pathway |
| US20210139477A1 (en) | 2019-07-16 | 2021-05-13 | Silverback Therapeutics, Inc. | Alk5 inhibitors, conjugates, and uses thereof |
| TW202118790A (zh) * | 2019-07-30 | 2021-05-16 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
| JP2022544785A (ja) | 2019-08-13 | 2022-10-21 | エルピス・バイオファーマシューティカルズ | 改変インターロイキン２受容体ベータアゴニスト |
| BR112022002720A2 (pt) | 2019-08-15 | 2022-10-11 | Silverback Therapeutics Inc | Formulações de conjugados de benzazepinas e usos das mesmas |
| CA3151322A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
| US20240058466A1 (en) | 2019-10-04 | 2024-02-22 | TAE Life Sciences | Antibody Compositions Comprising Fc Mutations and Site-Specific Conjugation Properties For Use In Treating Cancer, Immunological Disorders, and Methods Thereof |
| US20210130473A1 (en) | 2019-10-09 | 2021-05-06 | Silverback Therapeutics, Inc. | TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF |
| WO2021102332A1 (en) | 2019-11-22 | 2021-05-27 | Silverback Therapeutics, Inc. | Tgfbetar2 inhibitor-lrrc15 antibody conjugates and uses thereof |
| CN114867532A (zh) | 2019-12-18 | 2022-08-05 | 豪夫迈·罗氏有限公司 | 双特异性抗ccl2抗体 |
| KR20240035914A (ko) | 2019-12-27 | 2024-03-18 | 추가이 세이야쿠 가부시키가이샤 | 항ctla-4 항체 및 그의 사용 |
| KR102382593B1 (ko) * | 2020-01-29 | 2022-04-05 | 고려대학교 산학협력단 | pH-감응성 Fc 변이체 |
| TW202144395A (zh) | 2020-02-12 | 2021-12-01 | 日商中外製藥股份有限公司 | 用於癌症之治療的抗cd137抗原結合分子 |
| CA3175921A1 (en) | 2020-04-17 | 2021-10-21 | Zoetis Services Llc | Canine antibody variants |
| CA3176434A1 (en) | 2020-04-17 | 2021-10-21 | Zoetis Services Llc | Feline antibody variants |
| AU2021275453A1 (en) * | 2020-05-20 | 2023-02-02 | Zymeworks Bc Inc. | Heterodimeric Fc variants selective for Fc gamma RIIb |
| WO2021234655A2 (en) * | 2020-05-21 | 2021-11-25 | Cadila Healthcare Limited | Fc variant and preparation thereof |
| GB2595299B (en) | 2020-05-21 | 2022-08-03 | Mabsolve Ltd | Modified immunoglobulin FC regions |
| CN115803091A (zh) | 2020-05-22 | 2023-03-14 | 福迈康股份公司 | Ace2-fc融合蛋白及其用途 |
| US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
| WO2021251438A1 (ja) | 2020-06-10 | 2021-12-16 | 株式会社バイカ・セラピュティクス | エリスロポエチンポリペプチドを含む融合タンパク質 |
| EP4172193A1 (en) | 2020-06-29 | 2023-05-03 | Zoetis Services LLC | Feline antibody variants for improving stability |
| WO2022010921A1 (en) | 2020-07-06 | 2022-01-13 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting sars-cov-2 |
| EP4178678A1 (en) | 2020-07-07 | 2023-05-17 | Cancure, LLC | Mic antibodies and binding agents and methods of using the same |
| EP4204446A1 (en) | 2020-08-26 | 2023-07-05 | Flagship Pioneering Innovations VI, LLC | Antigen binding molecules targeting sars-cov-2 |
| JPWO2022044248A1 (da) | 2020-08-28 | 2022-03-03 | ||
| AU2021349301A1 (en) | 2020-09-28 | 2023-08-24 | Zoetis Services Llc | Canine antibody variants |
| CA3195049A1 (en) | 2020-09-29 | 2022-04-07 | Zoetis Services Llc | Feline antibody variants |
| WO2022090469A2 (en) | 2020-10-29 | 2022-05-05 | Formycon Ag | Ace2 fusion proteins and uses thereof |
| AU2021368272A1 (en) * | 2020-11-02 | 2023-06-08 | Attralus, Inc. | Sap fc fusion proteins and methods of use |
| EP4247851A1 (en) | 2020-11-20 | 2023-09-27 | Zoetis Services LLC | Bovine antibody variants |
| IL303732A (en) | 2020-12-18 | 2023-08-01 | Zoetis Services Llc | Mutations in constant regions in feline antibodies |
| EP4281186A1 (en) | 2021-01-22 | 2023-11-29 | Elpis Biopharmaceuticals | Anti-pd-l1 monoclonal antibodies and fusion proteins with interleukin-15 (il-15), interleukin-15 receptor 15 alpha or interleukin-2 |
| US20240059777A1 (en) | 2021-01-28 | 2024-02-22 | Zoetis Services Llc | Mutations in canine antibody constant regions |
| JP2024509543A (ja) | 2021-03-03 | 2024-03-04 | フォーマイコン アーゲー | ＡＣＥ２ Ｆｃ融合タンパク質の製剤 |
| IL308509A (en) | 2021-05-24 | 2024-01-01 | Vir Biotechnology Inc | Transgenic polypeptides |
| WO2022256820A1 (en) | 2021-06-03 | 2022-12-08 | Gensun Biopharma Inc. | Multispecific antagonists |
| EP4355775A1 (en) | 2021-06-18 | 2024-04-24 | F. Hoffmann-La Roche AG | Bispecific anti-ccl2 antibodies |
| IL308633A (en) | 2021-06-25 | 2024-01-01 | Chugai Pharmaceutical Co Ltd | Use of anti-CTLA-4 antibodies |
| AR126220A1 (es) | 2021-06-25 | 2023-09-27 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-ctla-4 |
| IL311043A (en) | 2021-08-30 | 2024-04-01 | Lassen Therapeutics 1 Inc | Anti-IL---11RA antibodies |
| EP4396233A1 (en) | 2021-09-02 | 2024-07-10 | DJS Antibodies Ltd | Polypeptides |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| EP4437112A1 (en) | 2021-11-24 | 2024-10-02 | Formycon AG | Improved ace2 fusion proteins |
| WO2023094571A1 (en) | 2021-11-25 | 2023-06-01 | Formycon Ag | Stabilization of ace2 fusion proteins |
| US11993644B2 (en) | 2022-05-06 | 2024-05-28 | Generate Biomedicines, Inc. | Antigen binding molecules targeting SARS-CoV-2 |
| WO2023220597A1 (en) | 2022-05-10 | 2023-11-16 | Elpis Biopharmaceuticals | Engineered interleukin-2 receptor beta reduced-binding agonist |
| WO2023239803A1 (en) | 2022-06-08 | 2023-12-14 | Angiex, Inc. | Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same |
| WO2024020164A2 (en) | 2022-07-21 | 2024-01-25 | Firefly Bio, Inc. | Glucocorticoid receptor agonists and conjugates thereof |
| US12110324B2 (en) | 2022-07-22 | 2024-10-08 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) |
| US20240190978A1 (en) | 2022-11-15 | 2024-06-13 | CSBioAsset LLC | Compositions and methods for immunomodulatory bifunctional fusion molecules |
| EP4386084A1 (en) | 2022-12-14 | 2024-06-19 | Formycon AG | Improved ace2 fusion proteins |
| TW202430560A (zh) | 2023-01-06 | 2024-08-01 | 美商拉森醫療公司 | 抗ｉｌ－１８ｂｐ抗體 |
| WO2024148240A1 (en) | 2023-01-06 | 2024-07-11 | Lassen Therapeutics 1, Inc. | ANTI-IL-11Rα ANTIBODIES FOR TREATING THYROID EYE DISEASE |
| TW202432591A (zh) | 2023-01-06 | 2024-08-16 | 美商拉森醫療公司 | 抗ｉｌ－１８ｂｐ抗體 |
| WO2024206214A1 (en) * | 2023-03-24 | 2024-10-03 | Paragon Therapeutics, Inc. | Fc fragments that bind fcrn and methods of use |
Family Cites Families (339)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2320801A (en) | 1940-10-03 | 1943-06-01 | Simons Leon | Method of coating metal |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| US3917002A (en) | 1971-10-15 | 1975-11-04 | Massey Ferguson Inc | Draft control linkage for a tractor |
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| JP2584613B2 (ja) | 1985-03-30 | 1997-02-26 | バリベ、マール | 組換えｄｎａ技術によってｄｎａ、ｒｎａ、ペプタイド、ポリペプタイド、または蛋白質を取得するための方法 |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6548640B1 (en) * | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| CA1340935C (en) | 1986-05-29 | 2000-03-28 | Ian F.C. Mckenzie | Fc gamma receptor |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5763192A (en) | 1986-11-20 | 1998-06-09 | Ixsys, Incorporated | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| JP3101690B2 (ja) * | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| NZ226414A (en) | 1987-10-02 | 1992-07-28 | Genentech Inc | Cd4 peptide adhesion variants and their preparation and use |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| US5576184A (en) * | 1988-09-06 | 1996-11-19 | Xoma Corporation | Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
| US5681566A (en) | 1988-10-24 | 1997-10-28 | 3I Research Exploitation Limited | Antibody conjugates with two or more covalently linked FC regions |
| US20030229208A1 (en) | 1988-12-28 | 2003-12-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5266491A (en) * | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
| JP3051411B2 (ja) * | 1989-03-14 | 2000-06-12 | 持田製薬株式会社 | 新規ｄｎａならびにそれを含有する発現プラスミド |
| US5683888A (en) | 1989-07-22 | 1997-11-04 | University Of Wales College Of Medicine | Modified bioluminescent proteins and their use |
| GB8923123D0 (en) | 1989-10-13 | 1989-11-29 | Connaught Lab | A vaccine for human immunodeficiency virus |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| JPH04505709A (ja) | 1989-11-07 | 1992-10-08 | ブリストル―マイアーズ スクイブ カンパニー | オリゴマー免疫グロブリン |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5292658A (en) | 1989-12-29 | 1994-03-08 | University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center | Cloning and expressions of Renilla luciferase |
| WO1991019515A1 (en) | 1990-06-21 | 1991-12-26 | The Board Of Trustees Of The Leland Stanford Junior University | Oligomeric immunoglobulin constant domain mutant with enhanced complement-mediated cytolytic activity |
| US5198342A (en) * | 1990-07-05 | 1993-03-30 | Immunex Corporation | DNA encoding IgA Fc receptors |
| WO1992004053A1 (en) | 1990-08-31 | 1992-03-19 | Bristol-Myers Sqibb Company | Homoconjugated immunoglobulins |
| GB9022545D0 (en) * | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
| AU658396B2 (en) | 1991-03-06 | 1995-04-13 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Humanized and chimeric monoclonal antibodies |
| WO1992015673A1 (en) | 1991-03-11 | 1992-09-17 | The University Of Georgia Research Foundation, Inc. | Cloning and expression of renilla luciferase |
| GB9105245D0 (en) | 1991-03-12 | 1991-04-24 | Lynxvale Ltd | Binding molecules |
| US6797492B2 (en) * | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
| WO1992022324A1 (en) | 1991-06-14 | 1992-12-23 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| US6329509B1 (en) | 1991-08-14 | 2001-12-11 | Genentech, Inc. | Anti-IgE antibodies |
| EP0861893A3 (en) * | 1991-09-19 | 1999-11-10 | Genentech, Inc. | High level expression of immunoglobulin polypeptides |
| US5623053A (en) * | 1992-01-10 | 1997-04-22 | California Institute Of Technology | Soluble mammal-derived Fc receptor which binds at a pH ranging from about 5.5 to 6.5 and releases at a pH ranging from about 7.5 to 8.5 |
| US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| EP0640094A1 (en) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| AU670125B2 (en) * | 1992-09-15 | 1996-07-04 | Immunex Corporation | Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists |
| PL174721B1 (pl) | 1992-11-13 | 1998-09-30 | Idec Pharma Corp | Przeciwciało monoklonalne anty-CD20 |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| WO1994013804A1 (en) | 1992-12-04 | 1994-06-23 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| US20030108548A1 (en) * | 1993-06-01 | 2003-06-12 | Bluestone Jeffrey A. | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| US5885573A (en) * | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
| GB9316989D0 (en) | 1993-08-16 | 1993-09-29 | Lynxvale Ltd | Binding molecules |
| WO1995007463A1 (en) | 1993-09-10 | 1995-03-16 | The Trustees Of Columbia University In The City Of New York | Uses of green fluorescent protein |
| GB9401182D0 (en) | 1994-01-21 | 1994-03-16 | Inst Of Cancer The Research | Antibodies to EGF receptor and their antitumour effect |
| WO1995021191A1 (en) | 1994-02-04 | 1995-08-10 | William Ward | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein |
| WO1995026403A1 (en) | 1994-03-29 | 1995-10-05 | Celltech Therapeutics Limited | Antibodies against e-selectin |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5541087A (en) * | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US5777079A (en) | 1994-11-10 | 1998-07-07 | The Regents Of The University Of California | Modified green fluorescent proteins |
| US6086875A (en) * | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
| US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| EP0805628B1 (en) | 1995-01-17 | 2003-05-02 | Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
| US5731168A (en) * | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6037453A (en) | 1995-03-15 | 2000-03-14 | Genentech, Inc. | Immunoglobulin variants |
| EP3103799B1 (en) | 1995-03-30 | 2018-06-06 | OSI Pharmaceuticals, LLC | Quinazoline derivatives |
| US6121022A (en) * | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| US6444789B1 (en) * | 1995-05-03 | 2002-09-03 | Applied Research Systems Ars Holding N.V. | CD16-II variants |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US6365161B1 (en) * | 1995-06-07 | 2002-04-02 | Medarex, Inc. | Therapeutic compounds comprised of anti-FC receptor binding agents |
| CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| US6352842B1 (en) | 1995-12-07 | 2002-03-05 | Diversa Corporation | Exonucease-mediated gene assembly in directed evolution |
| US6361974B1 (en) | 1995-12-07 | 2002-03-26 | Diversa Corporation | Exonuclease-mediated nucleic acid reassembly in directed evolution |
| US6358709B1 (en) | 1995-12-07 | 2002-03-19 | Diversa Corporation | End selection in directed evolution |
| US5790396A (en) | 1995-12-19 | 1998-08-04 | Kabushiki Kaisha Toshiba | Neutral point clamped (NPC) inverter control system |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| US5804387A (en) | 1996-02-01 | 1998-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | FACS-optimized mutants of the green fluorescent protein (GFP) |
| US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| US5876995A (en) | 1996-02-06 | 1999-03-02 | Bryan; Bruce | Bioluminescent novelty items |
| ATE279947T1 (de) | 1996-03-18 | 2004-11-15 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
| DE69729283T2 (de) | 1996-03-20 | 2005-05-25 | Immunomedics, Inc. | GLYKOSYLIERTE IgG ANTIKÖRPER |
| CN100503580C (zh) | 1996-04-12 | 2009-06-24 | 沃尼尔·朗伯公司 | 酪氨酸激酶的不可逆抑制剂 |
| WO1997043316A1 (en) | 1996-05-10 | 1997-11-20 | Beth Israel Deaconess Medical Center, Inc. | Physiologically active molecules with extended half-lives and methods of using same |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| EP0938506B1 (en) | 1996-07-16 | 2003-11-05 | Plückthun, Andreas, Prof. Dr. | Immunoglobulin superfamily domains and fragments with increased solubility |
| US5925558A (en) | 1996-07-16 | 1999-07-20 | The Regents Of The University Of California | Assays for protein kinases using fluorescent protein substrates |
| WO1998005787A1 (en) | 1996-08-02 | 1998-02-12 | Bristol-Myers Squibb Company | A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
| US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
| WO1998023289A1 (en) * | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| IL129767A0 (en) | 1996-12-12 | 2000-02-29 | Prolume Ltd | Apparatus and method for detecting and identifying infectious agents |
| EP0972023A2 (en) | 1997-01-21 | 2000-01-19 | Human Genome Sciences | Fc RECEPTORS AND POLYPEPTIDES |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| EP1255209A3 (en) | 1997-04-11 | 2009-02-11 | California Institute Of Technology | Apparatus and method for automated protein design |
| AU751331B2 (en) * | 1997-04-11 | 2002-08-15 | California Institute Of Technology | Apparatus and method for automated protein design |
| WO1998048032A2 (en) | 1997-04-21 | 1998-10-29 | Donlar Corporation | POLY-(α-L-ASPARTIC ACID), POLY-(α-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE |
| US20020062010A1 (en) * | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
| GB9712892D0 (en) | 1997-06-20 | 1997-08-20 | Eclagen Ltd | Identification of mhc binding peptides |
| US20040191256A1 (en) * | 1997-06-24 | 2004-09-30 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| US6188966B1 (en) * | 1998-02-10 | 2001-02-13 | Agilent Technologies | Reconstruction of multi-phase signals from repetitive samples |
| US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
| JP2002507410A (ja) | 1998-03-27 | 2002-03-12 | プロルーム・リミテッド | ルシフェラーゼ、蛍光タンパク質、ルシフェラーゼおよび蛍光タンパク質をコードする核酸および、診断、高処理スクリーニングおよび新規アイテムにおけるその使用 |
| US6242195B1 (en) * | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| US6194551B1 (en) * | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6528624B1 (en) * | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| AU3655899A (en) * | 1998-04-20 | 1999-11-08 | Regents Of The University Of California, The | Modified immunoglobulin molecules and methods for use thereof |
| CA2331607A1 (en) * | 1998-05-06 | 1999-11-11 | Temple University - Of The Commonwealth System Of Higher Education | Reversal of proinflammatory response by ligating the macrophage fc.gamma.ri receptor |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| GB9815157D0 (en) | 1998-07-13 | 1998-09-09 | Metron Designs Ltd | High resolution pulse width setting from relatively low frequency clocks |
| JP2002522063A (ja) * | 1998-08-17 | 2002-07-23 | アブジェニックス インコーポレイテッド | 増加した血清半減期を有する改変された分子の生成 |
| US6306926B1 (en) * | 1998-10-07 | 2001-10-23 | 3M Innovative Properties Company | Radiopaque cationically polymerizable compositions comprising a radiopacifying filler, and method for polymerizing same |
| US6403312B1 (en) * | 1998-10-16 | 2002-06-11 | Xencor | Protein design automatic for protein libraries |
| US7315786B2 (en) * | 1998-10-16 | 2008-01-01 | Xencor | Protein design automation for protein libraries |
| US20020048772A1 (en) * | 2000-02-10 | 2002-04-25 | Dahiyat Bassil I. | Protein design automation for protein libraries |
| US20030049654A1 (en) * | 1998-10-16 | 2003-03-13 | Xencor | Protein design automation for protein libraries |
| JP2003527072A (ja) | 1998-10-16 | 2003-09-16 | ゼンコー | 蛋白質ライブラリーに関する蛋白質設計オートメーション |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| DE69934967T2 (de) | 1998-12-08 | 2007-12-06 | Biovation Ltd. | Verfahren zur verminderung der immunogenität von proteinen |
| KR100940380B1 (ko) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6376246B1 (en) | 1999-02-05 | 2002-04-23 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
| EP1130093A1 (en) | 1999-01-19 | 2001-09-05 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
| US6221556B1 (en) | 1999-03-05 | 2001-04-24 | General Electric Company | Article for optical data storage device |
| EP1165775A2 (en) | 1999-03-05 | 2002-01-02 | Maxygen, Inc. | Recombination of insertion modified nucleic acids |
| EP2270147B2 (en) | 1999-04-09 | 2020-07-22 | Kyowa Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| US6663862B1 (en) * | 1999-06-04 | 2003-12-16 | Duke University | Reagents for detection and purification of antibody fragments |
| EP1212411A2 (en) | 1999-08-20 | 2002-06-12 | The Johns Hopkins University School Of Medicine | Methods and compositions for the construction and use of fusion libraries |
| US6649165B2 (en) | 1999-09-07 | 2003-11-18 | Walter Schubert | Method of blocking cytotoxic activity in patients with amyotrophic lateral sclerosis using soluble FcγRIII receptors |
| GB9922283D0 (en) | 1999-09-22 | 1999-11-17 | Kennedy Rheumatology Inst | Adenoviral vectors |
| AU8008100A (en) | 1999-10-19 | 2001-04-30 | Minergy Corp. | Processing of contaminated river sediment in a glass melting furnace |
| US7504256B1 (en) | 1999-10-19 | 2009-03-17 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing polypeptide |
| EP2363403B1 (en) | 1999-11-29 | 2016-04-20 | The Trustees of Columbia University in the City of New York | Isolation of five novel genes coding for new fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma |
| CN1163506C (zh) * | 1999-12-10 | 2004-08-25 | 上海华晨生物技术研究所 | 新的人细胞因子、其编码序列及用途 |
| WO2000022906A2 (en) | 1999-12-10 | 2000-04-27 | Wcl Wireless Commerce Ltd. Oy | Method and system for performing electronic auctions |
| DE60013099T2 (de) | 1999-12-27 | 2005-09-01 | Mitsubishi Denki K.K. | Funkkommunikationsgerät |
| AU2001241406A1 (en) | 2000-01-31 | 2001-08-07 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| NZ520472A (en) | 2000-02-03 | 2004-03-26 | Lennart Hammarstrom | Ruminant MHC class I-like Fc receptors |
| JP2003521933A (ja) | 2000-02-10 | 2003-07-22 | ゼンコー | タンパク質ライブラリーに関するタンパク質設計オートメーション |
| WO2001058949A2 (en) | 2000-02-11 | 2001-08-16 | Biogen, Inc. | Heterologous polypeptide of the tnf family |
| KR100812658B1 (ko) | 2000-02-25 | 2008-03-13 | 더 거번먼트 오브 더 유나이티드 스테이츠, 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비스즈 | 향상된 세포독성 및 수율의 항-이지에프알브이 3,에스씨에프브이에스, 이에 기초한 면역독소, 및 이의 이용방법 |
| US7056695B2 (en) | 2000-03-02 | 2006-06-06 | Xencor | TNF-α variants |
| US7687461B2 (en) | 2000-03-02 | 2010-03-30 | Xencor, Inc. | Treatment of TNF-α related disorders with TNF-α variant proteins |
| US7101974B2 (en) | 2000-03-02 | 2006-09-05 | Xencor | TNF-αvariants |
| US7244823B2 (en) | 2000-03-02 | 2007-07-17 | Xencor | TNF-alpha variants proteins for the treatment of TNF-alpha related disorders |
| US20010044111A1 (en) | 2000-03-20 | 2001-11-22 | Brian Carr | Method for generating recombinant DNA molecules in complex mixtures |
| US7449443B2 (en) | 2000-03-23 | 2008-11-11 | California Institute Of Technology | Method for stabilization of proteins using non-natural amino acids |
| CA2403425C (en) * | 2000-04-11 | 2013-08-27 | Genentech, Inc. | Multivalent antibodies and uses therefor |
| IL151348A0 (en) | 2000-04-13 | 2003-04-10 | Univ Rockefeller | Enhancement of antibody-mediated immune responses |
| FR2808944B1 (fr) | 2000-05-12 | 2002-08-09 | Agence Spatiale Europeenne | Procede et systeme de localisation par satellites |
| ES2259030T3 (es) | 2000-05-19 | 2006-09-16 | Scancell Limited | Anticuerpos humanizados frente al receptor del factor de crecimiento epidermico. |
| US6358733B1 (en) * | 2000-05-19 | 2002-03-19 | Apolife, Inc. | Expression of heterologous multi-domain proteins in yeast |
| US6586207B2 (en) | 2000-05-26 | 2003-07-01 | California Institute Of Technology | Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues |
| EA004875B1 (ru) | 2000-06-28 | 2004-08-26 | Хамар Бакулиш Мафатлал | Применение агента для обращения устойчивости к медикаментам у mycobacterium tuberculosis |
| WO2002004853A1 (fr) | 2000-07-07 | 2002-01-17 | Sugimoto, Motoichi | Dispositif de production d'energie infinie |
| WO2002005146A2 (en) | 2000-07-10 | 2002-01-17 | Xencor, Inc. | Method for disigning protein libraries with altered immunogenicity |
| FR2811735B1 (fr) | 2000-07-11 | 2002-09-20 | Asco Joucomatic | Vanne commande pneumatique |
| WO2002006469A2 (en) | 2000-07-18 | 2002-01-24 | Enchira Biotechnology Corporation | Methods of ligation mediated chimeragenesis utilizing populations of scaffold and donor nucleic acids |
| AU2001281714A1 (en) | 2000-07-19 | 2002-01-30 | Siemens Aktiengesellschaft | Method for providing software in radio-based cellular communications networks, and a communications network for implementing said method |
| US6724920B1 (en) | 2000-07-21 | 2004-04-20 | Trw Inc. | Application of human facial features recognition to automobile safety |
| US20030068649A1 (en) | 2000-09-14 | 2003-04-10 | Doberstein Stephen K. | Methods and compositions for the construction and use of fusion libraries |
| WO2002022826A2 (en) | 2000-09-14 | 2002-03-21 | Xencor, Inc. | Methods and compositions for the construction and use of fusion libraries |
| MXPA00009407A (es) | 2000-09-26 | 2004-12-08 | Mexicano Inst Petrol | Procedimiento para la preparacion de un catalizador monometalico de tipo zeolitico para la obtencion de gasolinas de alto octando mediante reformacion de naftas. |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) * | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| WO2002030954A1 (fr) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kogyo Co., Ltd. | Procede de purification d'un anticorps |
| CA2424602C (en) | 2000-10-06 | 2012-09-18 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-producing cell |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| AU2002213357A1 (en) | 2000-10-20 | 2002-05-06 | Idec Pharmaceuticals Corporation | Variant igg3 rituxan r and therapeutic use thereof |
| WO2002043658A2 (en) * | 2000-11-06 | 2002-06-06 | The Jackson Laboratory | Fcrn-based therapeutics for the treatment of auto-immune disorders |
| US7235643B2 (en) * | 2000-11-07 | 2007-06-26 | Morphotek, Inc. | Antibodies and methods for generating genetically altered antibodies with high affinity |
| GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
| US20040253242A1 (en) | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
| JP4336498B2 (ja) | 2000-12-12 | 2009-09-30 | メディミューン，エルエルシー | 延長した半減期を有する分子ならびにその組成物および用途 |
| WO2002066653A2 (en) | 2000-12-14 | 2002-08-29 | Xencor | Procaryotic libraries and uses |
| US6979556B2 (en) * | 2000-12-14 | 2005-12-27 | Genentech, Inc. | Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes |
| WO2002061090A2 (en) | 2000-12-14 | 2002-08-08 | Genentech, Inc. | Prokaryotically produced antibodies and uses thereof |
| US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2002061093A1 (en) | 2001-01-30 | 2002-08-08 | Degussa Ag | Nucleotide sequences which code for the otsa gene of c. glutamicum |
| US7430476B2 (en) | 2001-02-19 | 2008-09-30 | Merck Patent Gmbh | Method for identification of t-cell epitopes and use for preparing molecules with reduced immunogenicity |
| BR0207267A (pt) | 2001-02-19 | 2004-02-10 | Merck Patent Gmbh | Proteìnas artificiais com imunogenicidade reduzida |
| WO2002068698A2 (en) | 2001-02-22 | 2002-09-06 | Xencor, Inc. | Use of nucleic acid libraries to create toxicological profiles |
| AU2002251999A1 (en) | 2001-02-22 | 2002-09-12 | Xencor | Methods and compositions for the construction and use of fusion libraries using computational protein design methods |
| US20020168640A1 (en) | 2001-02-22 | 2002-11-14 | Min Li | Biochips comprising nucleic acid/protein conjugates |
| CN100489094C (zh) | 2001-03-23 | 2009-05-20 | 金克克国际有限公司 | 具有改变的免疫原性反应的蛋白质及制备和使用该蛋白质的方法 |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| EP1383800A4 (en) | 2001-04-02 | 2004-09-22 | Idec Pharma Corp | RECOMBINANT ANTIBODIES CO-EXPRESSED WITH GNTIII |
| US6792492B1 (en) * | 2001-04-11 | 2004-09-14 | Novell, Inc. | System and method of lowering overhead and latency needed to service operating system interrupts |
| US7117096B2 (en) | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
| KR20030033007A (ko) | 2001-05-31 | 2003-04-26 | 코울터 파머수티컬, 인코포레이티드 | 세포독소, 약물전구체, 링커 및 이에 유용한 안정화제 |
| EP1417232B1 (en) | 2001-06-13 | 2014-12-03 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
| JP2007520423A (ja) | 2001-07-10 | 2007-07-26 | ゼンコー・インコーポレイテッド | 改変された免疫原性を有するタンパク質ライブラリーを設計するためのタンパク質設計オートメーション |
| GB0118662D0 (en) | 2001-07-31 | 2001-09-19 | Univ Southampton | Binding agents |
| EP2180044A1 (en) * | 2001-08-03 | 2010-04-28 | GlycArt Biotechnology AG | Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity |
| ES2271321T3 (es) | 2001-08-03 | 2007-04-16 | Tyco Healthcare Group Lp | Marcador para ser usado con un aparato de marcacion de tejido. |
| AU2002326581A1 (en) | 2001-08-10 | 2003-03-03 | University Of Virginia Patent Foundation | Enhancing the efficacy of immunotherapies by supplementing with complement |
| US20030130827A1 (en) * | 2001-08-10 | 2003-07-10 | Joerg Bentzien | Protein design automation for protein libraries |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| US6911321B2 (en) | 2001-12-19 | 2005-06-28 | Genentech, Inc. | Non-human primate Fc receptors and methods of use |
| US20040093621A1 (en) * | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| EP1471938A4 (en) | 2002-01-09 | 2008-03-05 | Medarex Inc | HUMAN MONOCLONAL ANTIBODIES AGAINST CD30 |
| CA2472922A1 (en) | 2002-02-11 | 2003-08-21 | Genentech, Inc. | Antibody variants with faster antigen association rates |
| US20040002587A1 (en) * | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| AU2003248370A1 (en) | 2002-02-27 | 2003-09-09 | California Institute Of Technology | Computational method for designing enzymes for incorporation of amino acid analogs into proteins |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| WO2003074679A2 (en) * | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
| US7657380B2 (en) | 2003-12-04 | 2010-02-02 | Xencor, Inc. | Methods of generating variant antibodies with increased host string content |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| CN101143221A (zh) | 2002-03-15 | 2008-03-19 | 布赖汉姆妇女医院 | 适合治疗剂全身性递送的中央气道给药 |
| WO2003089624A2 (en) | 2002-03-25 | 2003-10-30 | Uab Research Foundation | Fc receptor homolog, reagents, and uses thereof |
| WO2003085119A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc$g(g) iiia |
| CA2491129A1 (en) | 2002-07-03 | 2004-01-15 | Brigham And Women's Hospital, Inc. | Central airway administration for systemic delivery of therapeutics |
| AU2003249014B2 (en) | 2002-07-09 | 2009-07-02 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US7425620B2 (en) * | 2002-08-14 | 2008-09-16 | Scott Koenig | FcγRIIB-specific antibodies and methods of use thereof |
| WO2004022717A2 (en) | 2002-09-05 | 2004-03-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Minimally immunogenic variants of humanized col-1 antibody against carcinoembryonic antigen |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| CA2499075A1 (en) | 2002-09-16 | 2004-03-25 | Elusys Therapeutics, Inc. | Production of bispecific molecules using polyethylene glycol linkers |
| US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| CA2499816C (en) * | 2002-09-27 | 2013-07-30 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| US7361740B2 (en) * | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| CA2502904C (en) | 2002-10-15 | 2013-05-28 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7365168B2 (en) | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP3263596A1 (en) | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| EP1581904A2 (en) | 2003-01-08 | 2005-10-05 | Xencor, Inc. | Novel proteins with altered immunogenicity |
| US7355008B2 (en) * | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US7960512B2 (en) * | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US8388955B2 (en) * | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| US7610156B2 (en) | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
| DK2335725T3 (da) | 2003-04-04 | 2017-01-23 | Genentech Inc | Højkoncentrerede antistof- og proteinformuleringer |
| WO2004087752A2 (en) | 2003-04-04 | 2004-10-14 | Ingenium Pharmaceuticals Ag | Spinster-like protein genes, expression products, non-human animal model: uses in human metabolic disorders |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
| AU2004257142A1 (en) | 2003-05-30 | 2005-01-27 | Alexion Pharmaceuticals, Inc. | Antibodies and fusion proteins that include engineered constant regions |
| SI1641483T1 (sl) | 2003-06-12 | 2008-08-31 | Lilly Co Eli | Fuzijski proteini |
| US20040254108A1 (en) | 2003-06-13 | 2004-12-16 | Jing Ma | Preparation and application of anti-tumor bifunctional fusion proteins |
| NZ544923A (en) | 2003-06-27 | 2009-02-28 | Biogen Idec Inc | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous anti-body solutions |
| CA2531482A1 (en) * | 2003-06-30 | 2005-01-20 | Centocor, Inc. | Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses |
| MXPA03005992A (es) | 2003-07-02 | 2005-04-11 | Rodriguez De La Garza Ricardo | Adaptador de telefonia internet inalambrico. |
| CN1829530A (zh) * | 2003-07-24 | 2006-09-06 | 依奈特制药公司 | 使用nk细胞增效化合物提高治疗性抗体功效的方法和组合物 |
| AU2004261198A1 (en) | 2003-07-26 | 2005-02-10 | Biogen Idec Ma Inc. | Altered antibodies having improved antigen-binding affinity |
| US20080050357A1 (en) | 2003-08-01 | 2008-02-28 | Claes Gustafsson | Systems and Methods for Antibody Engineering |
| US8007805B2 (en) * | 2003-08-08 | 2011-08-30 | Paladin Labs, Inc. | Chimeric antigens for breaking host tolerance to foreign antigens |
| NZ545776A (en) | 2003-08-22 | 2009-05-31 | Biogen Idec Inc | Improved antibodies having altered effector function and methods for making the same |
| EP1663306A2 (en) * | 2003-09-05 | 2006-06-07 | Genentech, Inc. | Antibodies with altered effector functions |
| EP1667702A2 (en) | 2003-09-10 | 2006-06-14 | Baxter International Inc., Baxter Healthcare Corp. | Peptides that inhibit complement activation |
| ES2737837T3 (es) | 2003-10-09 | 2020-01-16 | Ambrx Inc | Derivados poliméricos |
| EP1673395A1 (en) | 2003-10-15 | 2006-06-28 | PDL BioPharma, Inc. | Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| EP1697415A1 (en) * | 2003-11-12 | 2006-09-06 | Biogen Idec MA Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| EP1701979A2 (en) * | 2003-12-03 | 2006-09-20 | Xencor, Inc. | Optimized antibodies that target the epidermal growth factor receptor |
| UA86605C2 (ru) | 2004-01-12 | 2009-05-12 | Аплайд Молекьюлер Иволюшн, Инк. | Антитело, которое содержит вариант исходного человеческого fс-участка |
| MXPA06008496A (es) | 2004-02-02 | 2007-01-30 | Ambrx Inc | Polipeptidos de interferon humano modificados y sus usos. |
| AU2005227326B2 (en) | 2004-03-24 | 2009-12-03 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| MXPA06011805A (es) | 2004-04-16 | 2006-12-15 | Genentech Inc | Metodo para aumentar agotamiento de celulas b. |
| CA2563314A1 (en) | 2004-04-16 | 2005-12-08 | Macrogenics, Inc. | Fcyriib-specific antibodies and methods of use thereof |
| KR101297146B1 (ko) | 2004-05-10 | 2013-08-21 | 마크로제닉스, 인크. | 인간화 ＦｃγＲＩＩＢ 특이적 항체 및 그의 사용 방법 |
| KR100545720B1 (ko) | 2004-05-31 | 2006-01-24 | 메덱스젠 주식회사 | 당화된 면역글로불린 및 이를 포함하는 면역접합체 |
| WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
| JP2008505174A (ja) | 2004-07-15 | 2008-02-21 | ゼンコー・インコーポレイテッド | 最適化Ｆｃ変異体 |
| CA2574828C (en) | 2004-07-23 | 2018-11-13 | Genentech, Inc. | Crystallization of antibodies or fragments thereof |
| PL2213683T3 (pl) | 2004-08-04 | 2013-10-31 | Mentrik Biotech Llc | WARIANTY REGIONÓW Fc |
| ZA200701715B (en) | 2004-08-19 | 2008-07-30 | Genentech Inc | Polypeptide variants with altered effector function |
| AU2005286607B2 (en) | 2004-09-23 | 2011-01-27 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| WO2007024249A2 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| DK2325207T3 (da) | 2004-11-12 | 2017-06-06 | Xencor Inc | Fc-varianter med ændret binding til FcRn |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| US20070135620A1 (en) | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| CA2595169A1 (en) * | 2005-01-12 | 2006-07-20 | Xencor, Inc. | Antibodies and fc fusion proteins with altered immunogenicity |
| WO2006104989A2 (en) * | 2005-03-29 | 2006-10-05 | Verenium Corporation | Altered antibody fc regions and uses thereof |
| EP1871808A2 (en) | 2005-03-31 | 2008-01-02 | Xencor, Inc. | Fc VARIANTS WITH OPTIMIZED PROPERTIES |
| ES2523666T3 (es) | 2005-05-31 | 2014-11-28 | Board Of Regents, The University Of Texas System | Anticuerpos IgG1 con la parte Fc mutada para el aumento de unión al receptor FcRn y usos de los mismos |
| WO2007008943A2 (en) | 2005-07-08 | 2007-01-18 | Xencor, Inc. | Optimized anti-ep-cam antibodies |
| JP5105485B2 (ja) | 2005-08-10 | 2012-12-26 | マクロジェニクス，インコーポレーテッド | 変異型Ｆｃ領域を有する抗体の同定および工学的改変およびその使用方法 |
| AU2006299429B2 (en) * | 2005-10-03 | 2012-02-23 | Xencor, Inc. | Fc variants with optimized Fc receptor binding properties |
| CA2625998C (en) | 2005-10-06 | 2015-12-01 | Xencor, Inc. | Optimized anti-cd30 antibodies |
| US7790655B2 (en) | 2005-10-14 | 2010-09-07 | Medimmune, Llc | Cell display of antibody libraries |
| US20070087005A1 (en) | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
| JP2009525986A (ja) | 2006-02-03 | 2009-07-16 | メディミューン，エルエルシー | タンパク質製剤 |
| HUE066795T2 (hu) | 2006-03-15 | 2024-09-28 | Alexion Pharma Inc | Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral |
| PT2029173T (pt) | 2006-06-26 | 2016-11-02 | Macrogenics Inc | Anticorpos específicos fc rib e seus métodos de uso |
| WO2008008482A2 (en) | 2006-07-13 | 2008-01-17 | Genentech, Inc. | Altered br3-binding polypeptides |
| US20080112961A1 (en) | 2006-10-09 | 2008-05-15 | Macrogenics, Inc. | Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same |
| US20100143254A1 (en) | 2006-10-16 | 2010-06-10 | Medimmune, Llc | Molecules with reduced half-lives, compositions and uses thereof |
| GB0620934D0 (en) | 2006-10-20 | 2006-11-29 | Cambridge Antibody Tech | Protein variants |
| EP2494988B1 (en) | 2006-12-07 | 2015-09-30 | Novartis AG | Antagonist antibodies against EPHB3 |
| WO2008140603A2 (en) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
| WO2008079849A2 (en) | 2006-12-22 | 2008-07-03 | Genentech, Inc. | Antibodies to insulin-like growth factor receptor |
| WO2008134046A1 (en) | 2007-04-27 | 2008-11-06 | Genentech, Inc. | Potent, stable and non-immunosuppressive anti-cd4 antibodies |
| US20110008329A1 (en) | 2007-06-26 | 2011-01-13 | Medlmmune, Llc | Methods of Treating RSV Infections And Related Conditions |
| CN101998965B (zh) | 2007-11-01 | 2014-03-12 | 安斯泰来制药有限公司 | 免疫抑制性多肽与核酸 |
| CN101878258B (zh) * | 2007-11-28 | 2013-10-23 | 巴斯夫欧洲公司 | 液体稳定剂混合物 |
| ES2532461T3 (es) | 2007-12-26 | 2015-03-27 | Xencor, Inc. | Variantes de FC con enlazamiento alterado a FCRN |
| JP5220435B2 (ja) | 2008-02-20 | 2013-06-26 | オリンパスメディカルシステムズ株式会社 | 洗浄チューブ、及び内視鏡洗浄消毒装置 |
| US8037602B2 (en) | 2009-03-27 | 2011-10-18 | Eneron, Inc. | Methods of making energy efficient cookware |
| EP2598530A2 (en) | 2010-07-29 | 2013-06-05 | Xencor, Inc. | Antibodies with modified isoelectric points |
| LT2691417T (lt) | 2011-03-29 | 2018-10-25 | Roche Glycart Ag | Antikūno fc variantai |
| US20140294812A1 (en) | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| CA2972753C (en) | 2014-03-19 | 2023-09-26 | Duke University | Swarm immunization with envelopes from ch505 |
| US9710002B2 (en) | 2015-05-27 | 2017-07-18 | Texas Instruments Incorporated | Dynamic biasing circuits for low drop out (LDO) regulators |
| US11392902B2 (en) | 2017-06-06 | 2022-07-19 | United Parcel Service Of America, Inc. | Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery |
-
2005
- 2005-11-14 DK DK10178237.3T patent/DK2325207T3/da active
- 2005-11-14 CN CN201210181657.3A patent/CN102746404B/zh active Active
- 2005-11-14 EP EP10178207A patent/EP2332985A3/en not_active Withdrawn
- 2005-11-14 BR BRPI0517837-1A patent/BRPI0517837A/pt not_active Application Discontinuation
- 2005-11-14 EP EP10178224.1A patent/EP2325206B1/en active Active
- 2005-11-14 KR KR1020087029484A patent/KR101019525B1/ko active IP Right Grant
- 2005-11-14 CA CA2587617A patent/CA2587617C/en active Active
- 2005-11-14 US US11/274,065 patent/US9200079B2/en active Active
- 2005-11-14 KR KR1020077013230A patent/KR101027427B1/ko active IP Right Grant
- 2005-11-14 AU AU2005304624A patent/AU2005304624B2/en active Active
- 2005-11-14 JP JP2007541410A patent/JP4652414B2/ja active Active
- 2005-11-14 EP EP05851619A patent/EP1817340B1/en active Active
- 2005-11-14 DK DK05851619.6T patent/DK1817340T3/da active
- 2005-11-14 EP EP10178237.3A patent/EP2325207B1/en active Active
- 2005-11-14 EP EP14188077.3A patent/EP2845865A1/en not_active Withdrawn
- 2005-11-14 WO PCT/US2005/041220 patent/WO2006053301A2/en active Application Filing
- 2005-11-14 EP EP10177811A patent/EP2314618A3/en not_active Withdrawn
-
2007
- 2007-05-13 IL IL183158A patent/IL183158A/en active IP Right Grant
-
2011
- 2011-01-07 AU AU2011200066A patent/AU2011200066B2/en active Active
-
2014
- 2014-03-06 IL IL231390A patent/IL231390A0/en unknown
-
2015
- 2015-11-02 US US14/930,383 patent/US9803023B2/en active Active
-
2017
- 2017-09-20 US US15/710,322 patent/US11198739B2/en active Active
-
2021
- 2021-12-13 US US17/549,706 patent/US20220112307A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220112307A1 (en) | Fc VARIANTS WITH ALTERED BINDING TO FcRn | |
| US20210115147A1 (en) | Fc VARIANTS WITH ALTERED BINDING TO FcRn | |
| AU2017265140A1 (en) | Fc variants with altered binding to FcRn | |
| US20070135620A1 (en) | Fc variants with altered binding to FcRn | |
| AU2016203334A1 (en) | Fc variants with altered binding to FcRn |